公司資料
Mirum Pharmaceuticals 股價、新聞與催化劑
- 股票代碼:
- MIRM
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
83.10 USD (-0.41%)
收盤價
最後更新: 2026年10月22日
5.62B USD
市值
股價為何變動
截至 2026年10月22日，MIRM 下跌 0.41%，收於 $83.10。目前新聞監測窗口內未發現新的同公司新聞。
公司概覽
Rare Liver Disease Company
Mirum Pharmaceuticals develops and commercializes therapies for rare liver diseases, with particular expertise in disorders involving bile-acid dysregulation and severe cholestatic pruritus. Its model combines a global specialty commercial organization with late-stage internal development programs.
LIVMARLI Cholestatic Disease Franchise
LIVMARLI, an ileal bile acid transporter inhibitor, is marketed for cholestatic pruritus associated with Alagille syndrome and progressive familial intrahepatic cholestasis. The product anchors Mirum's commercial presence in pediatric and genetically defined liver diseases.
Established Bile-Acid Medicines
Mirum also markets bile-acid therapies for rare metabolic liver conditions, broadening its revenue base and relationships with hepatology centers. These products complement LIVMARLI and support a focused infrastructure for small patient populations requiring specialist diagnosis and long-term treatment.
Late-Stage Hepatology Pipeline
Volixibat is being developed for cholestatic pruritus in primary sclerosing cholangitis and primary biliary cholangitis. Brelovitug targets chronic hepatitis delta, while LIVMARLI lifecycle studies seek to extend the company's lead franchise into additional cholestatic settings.
Pipeline Beyond Liver Disease
Zilurgisertib is an ALK2 inhibitor for fibrodysplasia ossificans progressiva, and MRM-3379 is a PDE4D program for Fragile X syndrome. These assets expand Mirum into rare skeletal and neurodevelopmental diseases while preserving a specialty-pharma operating model.
未來催化劑
- FDA PDUFA decision for zilurgisertib in fibrodysplasia ossificans progressiva on September 26, 2026.
- AZURE-1 data for brelovitug in chronic hepatitis delta in the third quarter of 2026 and AZURE-4 data in the fourth quarter of 2026.
- Phase 3 EXPAND results for LIVMARLI in the fourth quarter of 2026.
- Phase 2b VANTAGE results for volixibat in primary sclerosing cholangitis in the first quarter of 2027.
- Potential volixibat NDA submission in primary sclerosing cholangitis in the first half of 2027, subject to FDA discussions.
近期新聞
新聞標題由機器翻譯，詳情為英文原文。
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。